OBJECTIVES: To estimate 6 months costs and quality of life (QoL) of patients with moderate to very severe COPD (GOLD criteria) who experienced a COPD exacerbation in comparison with control groups of similar COPD severity without exacerbation. METHODS: COPD in-and outpatients (Grade II 28; III 31; IV 31) with exacerbation (EXA-groups) were assessed retrospectively (3 month prior to exacerbation) and prospectively (3 month after exacerbation) and compared to controls (COgroups) of similar disease severity but stable health (3 month retrospective assessment). Direct costs included hospitalization, outpatient visits, laboratory tests, imaging, medication and rehabilitation. Indirect costs included short and long term disability payments. All costs were converted to a period of 180 days; health care costs used 2008 prices from the payer's perspective. A validated translation of the EQ5D was completed at inclusion day (all groups) and at final visit (EXA-groups). RESULTS: About 18% of grade-II and 75% grade-IV exacerbations were hospitalized, resulting in increased costs with COPD severity (6-months median: Grade II a846; III a2159; IV a3856; all p 0.05). Median 6-months costs in CO-groups were lower, although increasing from moderate to very severe COPD (Grade II a567; III a1610; IV a2084; all p 0.05). Exacerbation accounted for 8% (grade-II) to 31% (grade-IV) of total 6-months costs. Mean EQ5D utilities in the CO-groups and in the EXA-groups at final visit were comparable (moderate: 0.589 vs.0.636; severe: 0.623 vs. 0.591; very severe: 0.524 vs. 0.479; NS). Mean EXA-groups utilities at inclusion were significantly lower compared to final assessment (p 0.001) and decreasing with COPD severity (moderate: 0.524; severe: 0.390; very severe: 0.230), reflecting QoL impairment during COPD exacerbation and natural disease course. CONCLUSIONS: The BURDEN study confirmed for the Czech Republic a considerable economic burden of COPD. In accordance with international literature we found increased costs and decreased QoL for 1) COPD exacerbation vs. control in stable state, and 2) COPD progression. old) were identified by self reported diagnosis or ICD-9-CM code of 493. Patients with pregnancy, malignancy, kidney dialysis, immunodeficiency, chronic obstructive pulmonary disease, low body-mass-index(BMI) 18.5, or unemployed status were excluded. To investigate the impact of obesity, patients were classified as normal (BMI: 18.5-25) or obese(BMI: 30). Medical costs included all medical costs except for treatment costs of dental problems or injuries. Medical costs were estimated using a generalized linear model with a log link function and a gamma distribution. Loss of productivity was measured through the loss of workdays due to illness or injury for one year and valued using the hourly wage. Values of productivity loss were estimated using the two-part model. Costs attributable to obesity were estimated by the differences between actual and expected costs, holding the distribution of covariates obtained from the normal and obese patients in the model. All costs were converted to 2008 U.S. dollars using price indices. RESULTS: Among a total of identified 4,317 working adults with asthma, prevalence of normal weight is 34% while obese was 32%. The costs attributable to obesity were $2,384 (95%CI:$2,232-$2,536) for total medical treatment costs and $215 (95%CI $189-$241) for costs associated with productivity loss. The missed working days attributable to obesity were 2.4 days/year/patient (95%CI:2.1-2.7 days). The attributable costs to medical and productivity loss increased as patients became older or were female patients. CONCLUSIONS: Obese asthma patients have significantly higher costs associated with medical treatment and greater productivity loss compared to normal-weight asthma patients. Education aimed at weight control in asthma patients could result in a significant reduction in the economic burden of treating asthma patients and enhance productivity. Fluticasone; SAL/FP) and symptomatic (no maintenance) treatments of asthma with a developed transparent pharmacoeconomic model. METHODS: Lack of asthma control leads to unscheduled resources utilization and so growth of total cost (direct and indirect). Algorithm of OPTIMA model calculation includes 4 steps: 1) Analysis of weighted average cost of maintenance medicines based on dosing, average prices in reimbursement, and dose distribution in assessing population, and 2) Assessment of cost associated with controlled and uncontrolled asthma based on number of unscheduled resources utilization (emergency service, outpatient visits, inpatient stay, and work-off days) and their unit-cost (sources-current Russian legislation, RosStat data) as well as QoL. 3) Detection of frequency of controlled/uncontrolled asthma in arms based on clinical trials data. 4) Calculation of total cost in arms (cost of drug % controlled * cost of controlled % uncontrolled * cost of uncontrolled) and amount of saving. RESULTS: Weighted average cost of SAL/FP in Russia was 1 672 Rub (~ 40 EUR) per month. Cost associated with controlled and uncontrolled asthma were 320 Rub and 62,753 Rub (~a8 and a1,400) per patient per year, respectively; QoL scores were 0.75 and 0.49 respectiverly. Frequency of controlled asthma in SAL/FP arm was 75% (GOAL study) and so 25% patients were uncontrolled. Assumed frequency of controlled asthma using symptomatic treatment instead of SAL/FP 5%. Total costs were 35 991 Rub and 59,632 Rub (~a850 and a,1400) in maintenance and symptomatic arms, respectively; average QoL score were 69% and 50.3%. CONCLU-SIONS: The model allows transparent comparisons of different asthma treatment approaches. Maintenance treatment with SAL/FP was superior (less cost and higher QoL) to symptomatic treatment.
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PRS14 MEDICAL AND PRODUCTIVITY COSTS ATTRIBUTABLE TO OBESITY IN

PRS15
PRS16 COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING SMOKING CESSATION STRATEGIES IN HONG KONG
Lee KK, Lee VWY, Chow DP The Chinese University of Hong Kong, Shatin, Hong Kong OBJECTIVES: Smoking causes serious public health problems in Hong Kong. Effective smoking cessation strategies are required in order to cut public health budgets and save lives. The aim of this study is to estimate the cost effectiveness of a new smoking-cessation agent varenicline compared with the traditional strategies including bupropion, nicotine replacement treatment (NRT) and unaided cessation in Hong Kong. METHODS: A previously published Markov state-transition projection model was employed to estimate the life-long costs and effects of smoking cessation using varenicline, bupropion, NRT and unaided cessation from a societal perspective. Based on local epidemiology, a cohort of adult smokers was assumed to have a one-time quit attempt and was grouped by their genders and ages. Management costs and utilities of five smoking related diseases including chronic obstructive pulmonary disease (COPD), lung cancer, coronary heart disease (CHD), stroke and asthma were studied. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, diseaserelated morbidity and mortality rates were obtained from government statistics. Outcomes of the study in terms of benefits and costs were discounted at 5% after the first year of the study. Probabilistic sensitivity analysis was performed to assess the impact on the model outputs of uncertainty in certain model parameters including efficacies of the smoking cessation strategies, morbidity costs and morbidity utilities. RESULTS: Varenicline dominated among all the strategies with HKD106,573 ( US$13,663, HKD7.8 USD1)/QALY when compared with bupropion; HKD246,042 ( US$31,544)/QALY with NRT and HKD41,426 ( US$5,311)/ QALY with unaided cessation. The probabilities of varenicline being cost-effective were 77.9% when compared with bupropion, 69.3% with NRT and 88.3% with unaided cessation, at a willingness to pay of HKD50,000 (US$6410)/QALY. CONCLUSIONS: From the current study, varenicline appears to be a cost-effective smoking-cessation strategy when compared with the other existing strategies in Hong Kong.
PRS17 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY
Hampp C, Kauf TL, Saidi A, Winterstein AG University of Florida, Gainesville, FL, USA OBJECTIVES: To calculate the cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) hospitalization by risk group, using real-world cost and incidence estimates. METHODS: Decision trees were used to calculate incremental cost effectiveness ratios (ICERs) as the direct medical cost required to prevent one RSV-related hospitalization within 8 risk groups based on indication. Risk groups were defined by age and combinations of comorbid conditions (chronic lung disease [CLD] , congenital heart disease [CHD], or prematurity up to 32 weeks' gestational age), in accordance with treatment guidelines. 
PRS18 COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL ASSOCIATED TO BUDESONIDE FOR MAINTENANCE AND RELIEVER THERAPY (SYMBICORT SMART) VERSUS SALMETEROL ASSOCIATED TO FLUTICASONE IN THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA UNDER THE BRAZILIAN SOCIETAL PERSPECTIVE
Teich V 1 , Niskier F 1 , Pimentel A 2 , Alameddine M 2 1 MedInsight, Rio de Janeiro, Brazil, 2 AstraZeneca, Cotia, SP, Brazil OBJECTIVES: To develop a cost-effectiveness analysis of formoterol associated to budesonide for maintenance and reliever therapy (FB SMART) versus salmeterol associated do fluticasone (SF) in the treatment of patients with moderate to severe persistent asthma, under the Brazilian societal perspective. METHODS: A Markov model was developed to project costs and outcomes associated with disease progression of patients with moderate to severe persistent asthma receiving SMART therapy or SF in a one year time horizon. Weekly cycles were considered and the model structure consisted of four possible health states: disease control, use of oral corticoids (OC), hospitalization/emergency visit (H/ER) and death. The probabilities of having severe exacerbations (OC or H/ER) were extracted from the study by Kuna et al. All cause mortality rates were obtained from national epidemiological databases. Adverse events were not significantly different between comparators so were excluded from the model. Outcomes were expressed as severe exacerbations avoided (SEA) and only direct medical costs were included in the analysis. Resource use during hospitalization was estimated based on an expert panel. Maximum prices to consumer were obtained for drugs, and procedure costs were extracted from the Brazilian Classification of Medical Procedures (CBHPM). RESULTS: In one year, the average number of severe exacerbations was 0.2436 in the SMART group and 0.3928 in the SF group, resulting in 0.1492 severe exacerbations avoided. Total cost for the SMART and SF groups were R$1823.56 and R$1417.49, respectively (incremental cost R$406.07). The incremental cost-effectiveness ratio in 1 year was R$2721/SEA (US$1944 2005-PPPindex USD1.0 R$1.4). The variables that most influenced the results were the costs of SMART and SF therapy and the cost of hospitalization. CONCLUSIONS: SMART therapy reduces the risk of severe exacerbations when compared to SF in patients with moderate to severe persistent asthma, at a reasonable incremental cost, being a valuable alternative for these patients.
PRS19 IS IT TIME FOR SMOKING CESSATION PRODUCTS TO BE REIMBURSABLE IN THAILAND?
Thavorn K 1 , Chaiyakunapruk N 2 1 University of Toronto, Toronto, Ontario, Canada, 2 Center of Pharmaceutical Outcomes Research, Mueng, Phitsanulok, Thailand OBJECTIVES: Currently, no smoking cessation product is listed on National Essential List of Essential Medicine in Thailand. This study aimed to evaluate the cost-effectiveness of non-nicotine smoking cessation products in Thailand from health care system perspective. METHODS: A Markov model was used to simulate the effects of smoking-cessation on cohorts of 10,000 male smokers age 40 who regularly smoked 10-20 cigarettes a day. An incremental cost-effectiveness ratio of varenicline, bupropion, and nortriptyline compared to self-quitting was estimated. Transition probabilities were obtained from literature reviews, while medical care costs and utilization patterns were derived from a database of a Thai tertiary-care hospital and from the literature. The efficacy of all three products was obtained from a Bayesian metaanalysis. Costs of the medications were obtained from the Thai Drug and Medical Supply Information Center. Both costs and outcome were discounted at three percent. All costs were presented in 2008 Thai Baht. A series of sensitivity analysis including probabilistic sensitivity analysis, and cost-effectiveness acceptability curve were performed. RESULTS: In comparison to self-quitting, using a non-nicotine smoking cessation product results in cost-savings. Varenicline use results in the highest cost savings of 21,187 Baht or approximately US$605 and life-years gain of 0.25 years. The use of nortriptyline and bupropion was shown to lead to similar magnitude of both life years saved and cost-savings. Nortriptyline and bupropion use had cost-savings of 11,506 Baht and 10,734 Baht, respectively. Probabilistic sensitivity analyses demonstrate that the probability of cost-saving from using nortriptyline, varinicline, and bupropion for smoking cessation were 99%, 85%, and 80%, respectively. CONCLU-SIONS: From the perspective of the health care system, using of any of the three products yielded cost-savings and life-year gains. These findings may persuade Thai policy-makers to consider including these smoking cessation products on the National List of Essential Medicine. The main information source is the Monthly Services Survey, produced by Nacional Institute of Statistics and Geography. The monthly series begins in January 2005 and the last available observation is for March 2009. Natural logarithms of the dependent variables were constructed and differences-in-differences models were estimated by Ordinary Least Squares (OLS) to evaluate the impact using a control group conformed by Nuevo León and Jalisco, states that had similar behaviour before the date of implementation. RESULTS: Differences-in-differences estimations with robust p-values in parenthesis for the effect of implementation in restaurants are 0.144 (0.57) for direct employment; 0.78 (0.568) for wages; 0.050 (0.277) for income and 0.174 (0.09) for expenses. In the case of bars and night clubs: 0.004 (.976), 0.019 (0.883), 0.025 (0.56) and 0.049 (0.552) for direct employment, wages, income and expenses, respectively. Coefficients are non significant statistically. CON-CLUSIONS: With available data, we conclude that there is no statistical evidence at 95% confidence level that suggests that the implementation of the Mexico City's Non-Smokers Health Protection Act has had a negative economic effect in direct employment, wages, income and expenses in restaurants, bars and night clubs in Mexico City. To assess, in real life conditions, the costs, effects, and cost-effectiveness of Xolair® (omalizumab) as add-on versus conventional therapy in the management of Belgian patients with severe persistent allergic asthma inadequately controlled. METHODS: The same Markov model used for omalizumab initial reimbursement dossier was populated with data from a Belgian observational study, i.e. PERSIST study (n 160), especially set up to address questions raised by the Belgian authorities for omalizumab re-evaluation. The model takes into account four health states and links effectiveness data, real life resource use, and utility data. Medical resources use (drug treatment, laboratory tests and procedures, physician consultations, emergency room visits, and hospitalisations) were collected in PERSIST and costed from the perspective of the health care payer (i.e. INAMI/RIZIV patient). EQ-5D data were also collected during the study and used in the Markov model. RESULTS: Over a lifelong time horizon, the expected average numbers of life years (LYs) and QALYs per patient, for conventional therapy are 18.33 and 9.80, respectively. For omalizumab, the respective figures are 22.19 and 12.54. Over a lifelong time horizon, the expected average costs per patient are a44,548 and a124,726 for conventional therapy and omalizumab as add-on, respectively. Hence, omalizumab ICERs are a20,777/LY gained and a29,187/QALY gained. This compares very favourably (cf. substantial decrease in the ICERs) with the initial submission ICERs (i.e. a40,370/LY gained and a42,669/QALY gained). The sensitivity analyses performed show that results can somewhat vary according to the parameters changed. However, in all cases, the ICERs obtained with real life data are always markedly inferior to what was calculated in our initial submission. CONCLUSIONS: The pharmacoeconomic evaluation based on
PRS20 ECONOMIC EVALUATION OF THE IMPACT OF THE MEXICO CITY'S NON-SMOKERS HEALTH PROTECTION ACT
PRS21 COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE
The pharmacoeconomic evaluation based on data from a real life Belgian study confirms that omalizumab is cost-effective versus conventional therapy in the treatment of patients with severe persistent allergic asthma inadequately controlled.
PRS22 COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN.
Brosa M 1 , Díaz S 2 , Miravitlles M 3 , Gonzalez-Rojas N 4 , Nieves D 1 1 Oblikue Consulting, Barcelona, Spain, 2 Pfizer Spain, Madrid, Spain, 3 Hospital Clínic, Barcelona, Spain, 4 Boehringer Ingelheim, Sant Cugat del Vallés, Spain OBJECTIVES: The aim of this study is to analyze if tiotropium bromide is an efficient alternative respect to ipratropium bromide and standard therapy, in the management of chronic obstructive pulmonary disease (COPD) patients in Spain. METHODS: Efficiency of the different alternative options in COPD treatment was evaluated with a cost-effectiveness analysis. Tiotropium bromide was compared to ipratropium bromide and standard therapy by means of a cost-effectiveness analysis that estimates life years gained (LYG) with tiotropium respect to alternatives, by combining mortality associated to COPD exacerbations with rates of exacerbations taken from two meta-analysis of head to head clinical trials. The time horizon of the study was 13 years, the mean life expectancy in COPD patients included in the clinical trials with tiotropium. Uncertainty was studied by successive univariant sensitivity analysis of key parameters of the model and a probabilistic sensitivity analysis. All costs were expressed in a2008 and a 3% discount rate was applied to costs and effects. The analysis took the perspective of the Spanish National Health System (NHS). RESULTS: Incremental cost-effectiveness ratio (ICER) when treating COPD patients with tiotropium versus standard therapy was a2873/LYG, and in patients treated with tiotropium versus ipratropium bromide was a4208/LYG. Univariant sensitivity analysis showed that results where most sensitive to COPD severity and the future costs of surviving patients. CONCLUSIONS: Treating COPD patients with tiotropium is an efficient alternative respect ipratropium bromide or standard therapy for the Spanish NHS.
